Wells Fargo’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.97M | Buy |
221,081
+93,881
| +74% | +$1.78M | ﹤0.01% | 3054 |
|
|
2026
Q1 | $2.77M | Sell |
127,200
-40,525
| -24% | -$784K | ﹤0.01% | 3018 |
|
|
2025
Q4 | $3.61M | Sell |
167,725
-160,851
| -49% | -$3.39M | ﹤0.01% | 2971 |
|
|
2025
Q3 | $6.33M | Buy |
328,576
+55,520
| +20% | +$990K | ﹤0.01% | 2383 |
|
|
2025
Q2 | $4.67M | Buy |
273,056
+124,227
| +83% | +$5.3M | ﹤0.01% | 2530 |
|
|
2025
Q1 | $9.5M | Buy |
148,829
+33,371
| +29% | +$3.51M | ﹤0.01% | 1894 |
|
|
2024
Q4 | $14M | Buy |
115,458
+4,091
| +4% | +$501K | ﹤0.01% | 1603 |
|
|
2024
Q3 | $13.9M | Buy |
111,367
+3,797
| +4% | +$525K | ﹤0.01% | 1566 |
|
|
2024
Q2 | $17M | Sell |
107,570
-11,906
| -10% | -$1.53M | ﹤0.01% | 1348 |
|
|
2024
Q1 | $15.5M | Sell |
119,476
-4,717
| -4% | -$578K | ﹤0.01% | 1397 |
|
|
2023
Q4 | $12M | Sell |
124,193
-65,464
| -35% | -$6.28M | ﹤0.01% | 1555 |
|
|
2023
Q3 | $23M | Sell |
189,657
-1,513
| -0.8% | -$171K | 0.01% | 1007 |
|
|
2023
Q2 | $21.9M | Buy |
191,170
+56,133
| +42% | +$7.24M | 0.01% | 1068 |
|
|
2023
Q1 | $18.6M | Buy |
135,037
+18,775
| +16% | +$2.44M | 0.01% | 1176 |
|
|
2022
Q4 | $15.1M | Buy |
116,262
+1,272
| +1% | +$147K | ﹤0.01% | 1284 |
|
|
2022
Q3 | $12.7M | Buy |
114,990
+24,784
| +27% | +$2.5M | ﹤0.01% | 1343 |
|
|
2022
Q2 | $6.76M | Sell |
90,206
-27,875
| -24% | -$2.05M | ﹤0.01% | 1853 |
|
|
2022
Q1 | $9.22M | Buy |
118,081
+50,361
| +74% | +$3.86M | ﹤0.01% | 1902 |
|
|
2021
Q4 | $6.1M | Sell |
67,720
-24,873
| -27% | -$2.13M | ﹤0.01% | 2375 |
|
|
2021
Q3 | $8.56M | Buy |
92,593
+14,737
| +19% | +$1.14M | ﹤0.01% | 2349 |
|
|
2021
Q2 | $6.05M | Sell |
77,856
-17,024
| -18% | -$1.29M | ﹤0.01% | 2690 |
|
|
2021
Q1 | $7.07M | Sell |
94,880
-567,948
| -86% | -$52.4M | ﹤0.01% | 2510 |
|
|
2020
Q4 | $113M | Buy |
662,828
+76,438
| +13% | +$11.3M | 0.03% | 585 |
|
|
2020
Q3 | $82.3M | Buy |
586,390
+35,348
| +6% | +$5.37M | 0.02% | 643 |
|
|
2020
Q2 | $88.4M | Buy |
551,042
+63,985
| +13% | +$8.71M | 0.03% | 595 |
|
|
2020
Q1 | $47.6M | Sell |
487,057
-22,096
| -4% | -$2.53M | 0.02% | 781 |
|
|
2019
Q4 | $65.7M | Buy |
509,153
+16,553
| +3% | +$1.67M | 0.02% | 794 |
|
|
2019
Q3 | $37.1M | Sell |
492,600
-183,908
| -27% | -$21.7M | 0.01% | 1074 |
|
|
2019
Q2 | $103M | Buy |
676,508
+42,463
| +7% | +$5.16M | 0.03% | 566 |
|
|
2019
Q1 | $75.6M | Buy |
634,045
+10,037
| +2% | +$1.29M | 0.02% | 684 |
|
|
2018
Q4 | $68.1M | Buy |
624,008
+90,108
| +17% | +$11.3M | 0.02% | 668 |
|
|
2018
Q3 | $86.2M | Buy |
533,900
+177,528
| +50% | +$24.3M | 0.02% | 649 |
|
|
2018
Q2 | $47.1M | Sell |
356,372
-271,676
| -43% | -$25.6M | 0.01% | 942 |
|
|
2018
Q1 | $46.5M | Buy |
628,048
+340,802
| +119% | +$22.7M | 0.01% | 944 |
|
|
2017
Q4 | $16M | Sell |
287,246
-13,595
| -5% | -$720K | ﹤0.01% | 1630 |
|
|
2017
Q3 | $13.6M | Buy |
300,841
+192,364
| +177% | +$7.69M | ﹤0.01% | 1712 |
|
|
2017
Q2 | $3.66M | Buy |
108,477
+23,767
| +28% | +$774K | ﹤0.01% | 2695 |
|
|
2017
Q1 | $2.51M | Buy |
84,710
+16,620
| +24% | +$514K | ﹤0.01% | 3014 |
|
|
2016
Q4 | $1.87M | Buy |
68,090
+30,093
| +79% | +$1.21M | ﹤0.01% | 3218 |
|
|
2016
Q3 | $2.33M | Buy |
37,997
+989
| +3% | +$29.9K | ﹤0.01% | 2839 |
|
|
2016
Q2 | $706K | Buy |
37,008
+51
| +0.1% | +$945 | ﹤0.01% | 3703 |
|
|
2016
Q1 | $721K | Sell |
36,957
-3,618
| -9% | -$63.2K | ﹤0.01% | 3619 |
|
|
2015
Q4 | $1.56M | Sell |
40,575
-109,882
| -73% | -$3.56M | ﹤0.01% | 3172 |
|
|
2015
Q3 | $4.83M | Sell |
150,457
-132,180
| -47% | -$4.48M | ﹤0.01% | 2355 |
|
|
2015
Q2 | $8.6M | Sell |
282,637
-13,681
| -5% | -$280K | ﹤0.01% | 2021 |
|
|
2015
Q1 | $3.94M | Buy |
296,318
+19,295
| +7% | +$257K | ﹤0.01% | 2549 |
|
|
2014
Q4 | $4.01M | Buy |
277,023
+240,340
| +655% | +$4.07M | ﹤0.01% | 2506 |
|
|
2014
Q3 | $773K | Buy |
36,683
+11,656
| +47% | +$263K | ﹤0.01% | 3638 |
|
|
2014
Q2 | $745K | Buy |
25,027
+5,671
| +29% | +$179K | ﹤0.01% | 3704 |
|
|
2014
Q1 | $465K | Sell |
19,356
-1,515
| -7% | -$38.6K | ﹤0.01% | 3920 |
|
|
2013
Q4 | $425K | Sell |
20,871
-51,219
| -71% | -$1.52M | ﹤0.01% | 3876 |
|
|
2013
Q3 | $3.4M | Sell |
72,090
-13,919
| -16% | -$536K | ﹤0.01% | 2486 |
|
|
2013
Q2 | $3.27M | Buy |
+86,009
| New | +$3.08M | ﹤0.01% | 2438 |
|
Other funds holding SRPT
EAM
Wells Fargo's SRPT Position: Q2 2026 in Review
Wells Fargo increased its Sarepta Therapeutics (SRPT) stake by 74% in Q2 2026, buying an estimated $1.78M and bringing the position to 221,081 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #3054.
Wells Fargo first reported a position in SRPT in Q2 2013 and has held it in 53 quarters since. The position peaked at $113M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.
- Wells Fargo held 221,081 shares of Sarepta Therapeutics worth $3.97M as of Q2 2026.
- Wells Fargo bought 93,881 Sarepta Therapeutics shares in Q2 2026, an estimated $1.78M.
- Sarepta Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3054 holding.
- Wells Fargo first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Wells Fargo's Sarepta Therapeutics position peaked at $113M in Q4 2020.
- 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.